Piper Sandler lowered the firm’s price target on PacBio (PACB) to $2 from $2.50 following quarterly results. The firm keeps a Neutral rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Unusually active option classes on open February 18th
- Largest borrow rate increases among liquid names
- Pacific Biosciences: Hold Rating Amid Revenue Guidance Challenges and Positive Vega System Prospects
- PacBio grants equity incentive award to new employee
- PacBio’s 2024 Earnings: Growth Amid Challenges